An Anti-Estrogenic Lignan Glycoside, Tracheloside, from Seeds of Carthamus Tinctorius

Total Page:16

File Type:pdf, Size:1020Kb

An Anti-Estrogenic Lignan Glycoside, Tracheloside, from Seeds of Carthamus Tinctorius Biosci. Biotechnol. Biochem., 70 (11), 2783–2785, 2006 Note An Anti-Estrogenic Lignan Glycoside, Tracheloside, from Seeds of Carthamus tinctorius y Hye Hyun YOO,1;2 Jeong Hill PARK,1 and Sung Won KWON1; 1College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 151-742, Korea 2Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology, Seoul 136-791, Korea Received May 25, 2006; Accepted July 11, 2006; Online Publication, November 7, 2006 [doi:10.1271/bbb.60290] The lignan glycoside, tracheloside, was isolated from S. Han of Seoul National University, Korea. A voucher seeds of Carthamus tinctorius (Compositae) as an anti- specimen of this plant (NP-03-011) has been deposited estrogenic principle against cultured Ishikawa cells by at the Herbarium of the College of Pharmacy, Seoul employing a bioassay-linked HPLC-ELSD method. National University, Korea. Milled seeds of C. tinctorus Tracheloside significantly decreased the activity of (2.0 kg) were extracted with MeOH. After filtering and alkaline phosphatase (AP), an estrogen-inducible mark- evaporating the solvent, the resulting extract was er enzyme, with an IC50 value of 0.31 g/ml, a level of suspended in water, and then partitioned between EtOAc inhibition comparable to that of tamoxifen (IC50 = and n-BuOH to afford dried EtOAc-soluble (8 g) and 0.43 g/ml). n-BuOH-soluble residues (6.5 g). Each of the residues was tested against Ishikawa cells, and the EtOAc- Key words: Carthamus tinctorius; tracheloside; anti-es- soluble fraction was found to be active (Inhibition at trogenic activity; Ishikawa cell; bioassay- 4 mg/ml = 92%). Fifty microliters of the EtOAc-soluble linked HPLC-ELSD residue (20 mg/ml MeOH) was injected into an ODS column (Kanto Mightysil, RP-18, 5 mm, 4:6 Â 250 mm), Interest in estrogen analogs as antagonists has and the column was eluted with 1% acetic acid in increased tremendously because of the clinical applica- CH3CN/1% acetic acid in H2O (30/70, 0 min ! 100/0, tion of anti-estrogens for treating breast cancer and their 15 min ! 100/0, 30 min) at a rate of 1 ml/min. The possible chemopreventive effects on women who are at eluent from the column was introduced through a micro- high risk for developing breast cancer. Indeed, tamox- splitter valve into ELSD and a fraction collector in the ifen, a non-steroidal anti-estrogen, is extensively utilized ratio of 1:9, respectively. The eluent collected in a 96- in the prevention and treatment of breast cancer in well plate was dried and used for determining the anti- women. However, the effectiveness of tamoxifen in estrogenic activity. Figure 1 displays the HPLC-ELSD treating breast cancer has been limited, because of the chromatogram (A) and the bioactivity profile (B) of possible increased risk of endometrial carcinoma.1) the EtOAc-soluble fraction of C. tinctorius seeds. The Therefore, the search for novel anti-estrogens without activity profile indicates a retention time for the side effects, especially those from natural origins, has component exhibiting strong AP inhibitory activity of been extensive. As part of our current project to discover around 11 min, and the HPLC-ELSD chromatogram novel plant-derived anti-estrogens as chemopreventive shows a peak corresponding to the active component. agents, we utilized Ishikawa cells. Ishikawa cells are On this basis, the active component, tracheloside, was estrogen responsive human endometrial adenocarcinoma isolated by using prep-TLC. cells, and the alkaline phosphatase (AP) activity in these The anti-estrogenic activity was evaluated by using cells is markedly stimulated by estrogens.2) We report Ishikawa cells as described previously.3) Briefly, here on the isolation of the active component from Ishikawa cells provided by R. B. Hochberg (Yale C. tinctorius seeds and the biological potential of University, New Haven, CT, USA) were incubated its anti-estrogenic activity by using a bioassay-linked overnight with an estrogen-free DMEM/F12 medium in HPLC-ELSD method. 96-well plates (5 Â 104/well). To determine the anti- Seeds of Carthamus tinctorus L. (Compositae) were estrogenic activity, the cells were incubated with 1 nM purchased from the Kyung-Dong Market, Seoul, Korea estradiol (E2) and a test compound in a total volume of in March 2001 and were identified by Emeritus Prof. D. 200 ml of medium/well at 37 C for 4 days. The enzyme y To whom correspondence should be addressed. Tel: +82-2-880-7844; Fax: +82-2-886-7844; E-mail: [email protected] 2784 H. H. YOO et al. Fig. 1. HPLC-ELSD Chromatogram (A) and Anti-Estrogenic Activity Profile (B) of the EtOAc-Soluble Fraction from Carthamus tinctorius Seeds. activity was measured by reading at 405 nm the O liberation of p-nitrophenol with a microplate reader at OH CH3O 15-s intervals to give a total of 16–20 readings. The maximum slope of the lines generated from the kinetic O data was calculated by using a computer program. The GlcO percentage induction for determining the estrogenic H activity was calculated as [(slope for sample À slope for cells)/(slope for estrogen À slope for cells)] Â 100. To determine the anti-estrogenic activity, the percentage OCH induction was determined as [(slope for sample À slope 3 for cells)/(slope for DMSO À slope for cells)] Â 100. OCH3 The data represent the average of triplicate determina- tions. Tracheloside alone did not significantly induce Fig. 2. Chemical Structure of Tracheloside. AP activity in the absence of estradiol (E2). However, when the cells were treated with 1 nM E2, the AP activity was increased by approximately 10-fold, and the phytoestrogens may have beneficial effects on breast induction was markedly inhibited by tracheloside in a and prostate cancer which are both influenced by 6) dose-dependent manner (Fig. 3). The IC50 value for hormones. Tracheloside, a lignan glycoside, is known tracheloside was 0.31 mg/ml, comparable to that of to occur abundantly in the Trachelospermum species. tamoxifen (IC50 = 0.43 mg/ml). Tracheloside had no Lignan glycosides are generally known to be phytoes- effect on the cell viability at any of the concentrations trogens or cytotoxic agents.7) Tracheloside is structurally tested, as judged by parallel studies of cytotoxicity with similar to the well-known lignan phytoestrogen, arctiin, a sulforhodamine B assay (data not shown).4) in which side-chain C-2 of a five-membered ring is A variety of plant chemicals that bind to the estrogen changed from a hydrogen to a hydroxyl group (Fig. 2), receptor have been identified and may exert estrogenic- and thus tracheloside can also be considered to function like action by various mechanisms.5) Representative of as a phytoestrogen. It is noteworthy that arctiin is these phytoestrogens are the isoflavonoids and diphe- transformed to estrogenic and anti-estrogenic substances nolic compounds contained in the bean subfamily of by human intestinal bacteria,8) suggesting that trachelo- Leguminosae. However, the potency of most of these side might also be metabolized by human intestinal phytoestrogens is low compared to such endogenous or bacteria in the same manner. There is therefore the synthetic steroid estrogens as 17 -estradiol or ethinyl- possibility that an intake of tracheloside via the diet or estradiol, and these phytoestrogens therefore sometimes a herbal medicine such as safflower seeds might show exhibit antagonistic actions against estrogens. Epide- estrogenic action in the body, contrary to the effect of its miological data have suggested that the consumption of constituent, tracheloside. In addition, tracheloside and An Anti-Estrogenic Lignan Glycoside 2785 120 100 80 60 40 20 Induction of AP (%) 0 0 0.5 1 1.5 2 –20 Concentration (µg/ml) Fig. 3. Effect of Tracheloside on the Induction of AP in Ishikawa Cells. The cells were treated with various concentrations of tracheloside with ( ) or without ( )E2(1nM) for 96 hr in an estrogen-free medium, and the AP level was measured by using p-nitrophenyl phosphate as the substrate. Each value is presented as the mean Æ S.E. arctiin are known to be respectively transformed into the Effects of steroid hormones and antisteroids on alkaline aglycones, trachelogenin and arctigenin by gastric juice phosphatase activity in human endometrial cancer cells and intestinal bacteria in rats.9) Further studies on the in (Ishikawa line). Cancer Res., 46, 2771–2774 (1986). vivo metabolism of tracheloside will be needed to clarify 3) Pisha, E., and Pezzuto, J. M., Cell-based assay for the the estrogen-related effect of tracheloside in vivo. determination of estrogenic and anti-estrogenic activ- ities. Methods Cell Sci., 19, 37–43 (1997). There have been few reports to date concerning the 4) Rubinstein, L. V., Shoemaker, R. H., Paull, K. D., anti-estrogenic properties of lignans, and some have Simon, R. M., Tosini, S., Skehan, P., Scudiero, D. A., 10) been to be reported inactive in anti-estrogenic tests. Monks, A., and Boyd, M. R., Comparison of in vitro Therefore, this result for the anti-estrogenic activity of anticancer-drug-screening data generated with a tetrazo- tracheloside in Ishikawa cells will be helpful to our lium assay versus a protein assay against a diverse panel understanding of the hormone-like action of lignans and of human tumor cell lines. J. Natl. Cancer Inst., 82, will provide informative data concerning the effect of 1113–1118 (1990). safflower seeds as a herbal medicine, although further 5) Davis, S. R., Dalais, F. S., Simpson, E. R., and Murkies, studies using in vivo models are needed. The LC-ELSD A. L., Phytoestrogens in health and disease. Recent Prog. method used in this investigation in conjunction with the Horm. Res., 54, 185–210 (1999).
Recommended publications
  • UFC PROHIBITED LIST Effective June 1, 2021 the UFC PROHIBITED LIST
    UFC PROHIBITED LIST Effective June 1, 2021 THE UFC PROHIBITED LIST UFC PROHIBITED LIST Effective June 1, 2021 PART 1. Except as provided otherwise in PART 2 below, the UFC Prohibited List shall incorporate the most current Prohibited List published by WADA, as well as any WADA Technical Documents establishing decision limits or reporting levels, and, unless otherwise modified by the UFC Prohibited List or the UFC Anti-Doping Policy, Prohibited Substances, Prohibited Methods, Specified or Non-Specified Substances and Specified or Non-Specified Methods shall be as identified as such on the WADA Prohibited List or WADA Technical Documents. PART 2. Notwithstanding the WADA Prohibited List and any otherwise applicable WADA Technical Documents, the following modifications shall be in full force and effect: 1. Decision Concentration Levels. Adverse Analytical Findings reported at a concentration below the following Decision Concentration Levels shall be managed by USADA as Atypical Findings. • Cannabinoids: natural or synthetic delta-9-tetrahydrocannabinol (THC) or Cannabimimetics (e.g., “Spice,” JWH-018, JWH-073, HU-210): any level • Clomiphene: 0.1 ng/mL1 • Dehydrochloromethyltestosterone (DHCMT) long-term metabolite (M3): 0.1 ng/mL • Selective Androgen Receptor Modulators (SARMs): 0.1 ng/mL2 • GW-1516 (GW-501516) metabolites: 0.1 ng/mL • Epitrenbolone (Trenbolone metabolite): 0.2 ng/mL 2. SARMs/GW-1516: Adverse Analytical Findings reported at a concentration at or above the applicable Decision Concentration Level but under 1 ng/mL shall be managed by USADA as Specified Substances. 3. Higenamine: Higenamine shall be a Prohibited Substance under the UFC Anti-Doping Policy only In-Competition (and not Out-of- Competition).
    [Show full text]
  • Pp375-430-Annex 1.Qxd
    ANNEX 1 CHEMICAL AND PHYSICAL DATA ON COMPOUNDS USED IN COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES AND HORMONAL MENOPAUSAL THERAPY Annex 1 describes the chemical and physical data, technical products, trends in produc- tion by region and uses of estrogens and progestogens in combined estrogen–progestogen contraceptives and hormonal menopausal therapy. Estrogens and progestogens are listed separately in alphabetical order. Trade names for these compounds alone and in combination are given in Annexes 2–4. Sales are listed according to the regions designated by WHO. These are: Africa: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia and Zimbabwe America (North): Canada, Central America (Antigua and Barbuda, Bahamas, Barbados, Belize, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago), United States of America America (South): Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guyana, Paraguay,
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,723,320 B2 Bunschoten Et Al
    US007723320B2 (12) United States Patent (10) Patent No.: US 7,723,320 B2 Bunschoten et al. (45) Date of Patent: May 25, 2010 (54) USE OF ESTROGEN COMPOUNDS TO DE 23,36434. A 4, 1975 INCREASE LIBDO IN WOMEN WO WO96 O3929 A 2, 1996 (75) Inventors: Evert Johannes Bunschoten, Heesch OTHER PUBLICATIONS (NL); Herman Jan Tijmen Coelingh Bennink, Driebergen (NL); Christian Holinka CF et al: “Comparison of Effects of Estetrol and Taxoxifen Franz Holinka, New York, NY (US) with Those of Estriol and Estradiol on the Immature Rat Uterus'; Biology of Reproduction; 1980; pp. 913-926; vol. 22, No. 4. (73) Assignee: Pantarhei Bioscience B.V., Al Zeist Holinka CF et al; "In-Vivo Effects of Estetrol on the Immature Rat (NL) Uterus'; Biology of Reproduction; 1979: pp. 242-246; vol. 20, No. 2. Albertazzi Paola et al.; "The Effect of Tibolone Versus Continuous Combined Norethisterone Acetate and Oestradiol on Memory, (*) Notice: Subject to any disclaimer, the term of this Libido and Mood of Postmenopausal Women: A pilot study': Data patent is extended or adjusted under 35 base Biosis "Online!; Oct. 31, 2000: pp. 223-229; vol. 36, No. 3; U.S.C. 154(b) by 1072 days. Biosciences Information Service.: Philadelphia, PA, US. Visser et al., “In vitro effects of estetrol on receptor binding, drug (21) Appl. No.: 10/478,264 targets and human liver cell metabolism.” Climacteric (2008) 11(1) Appx. II: 1-5. (22) PCT Filed: May 17, 2002 Visser et al., “First human exposure to exogenous single-dose oral estetrol in early postmenopausal women.” Climacteric (2008) 11(1): (86).
    [Show full text]
  • Prohibited List
    PROHIBITED LIST This List shall come into effect on 1 January 201X THE 201X PROHIBITED LIST Valid 1 January 201X In accordance with ARCI-011-015/ARCI-025-015 all substances in the categories below shall be strictly prohibited unless otherwise noted. Any reference to substances in this section does not alter the requirements for testing concentrations in race day samples. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES Nothing in this list shall alter the requirements of post-race testing. S0. NON-APPROVED SUBSTANCES Any pharmacologic substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human or veterinary use (e.g., drugs under pre-clinical or clinical development, discontinued drugs, and designer drugs) is prohibited at all times. S00. THERAPEUTIC SUBSTANCES Therapeutic substances that are not otherwise prohibited pursuant to this list are permitted provided such substances: Have current approval for use in human, horse, or other animal by any governmental regulatory health authority in the jurisdiction where the horse is located S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) 1.1. Exogenous* AAS, including: 1-androstenediol (5α-androst-1-ene-3β,17β-diol ); 1-androstenedione (5α- androst-1-ene-3,17-dione); bolandiol (estr-4-ene-3β,17β-diol ); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol
    [Show full text]
  • Estrogen, Cosmetics, and Labeling in Canadian Regulatory Practices, 1939–1953
    Potency and Power: Estrogen, Cosmetics, and Labeling in Canadian Regulatory Practices, 1939–1953 Lara Tessaro Kent Law School, University of Kent [email protected] Abstract Building on a rich body of feminist scholarship on estrogen, this account interrogates how potent estrogenic cosmetics and consumer product labels emerged together, through the regulatory practices of scientists and lawyers, in mid-century Canada. Composed from archival and other primary sources, the story traces the development of Canada’s first cosmetic regulations – which applied only to cosmetic products containing estrogens. In 1944, “sex hormones” had been the first substances for which the Department of National Health and Welfare adopted labels in lieu of dose or potency standards under the Food and Drugs Act. With dose-response thresholds thus written out of the Sex Hormone Regulations, in 1949, regulators devised a new type of consumer product label that warned women to use estrogenic cosmetic products “with care”. Further regulatory amendments in 1950 appeared, on their face, to require positive proof of safety for estrogenic cosmetics. However, through varied administrative and enforcement practices that hinged upon “directions for use” in product labels, National Health officials quietly reintroduced dose-response logics back into estrogen regulation. As legal technologies for disciplining women consumers to regulate their own exposures, product labels were becoming instrumental. With labeling, estrogen catalyzed an early example of risk regulation in Canada. Introduction Today, endocrine disruption is a well-established phenomenon. The fact that Tessaro, Lara. (2020). Potency and power: Estrogen, cosmetics, and labeling in Canadian regulatory practices, 1939–1953. Catalyst: Feminism, Theory, Technoscience, 6(1), page 1-43.
    [Show full text]
  • For Selected Potent Endocrine Disrupting Steroids: Development and Application to Environmental Studies
    Rapid and Sensitive Enzyme-Linked Immunosorbent Assays (ELISAs) for Selected Potent Endocrine Disrupting Steroids: Development and Application to Environmental Studies Chatchaporn Uraipong Thesis submitted in partial fulfillment of the requirement for the Degree of Master of Science (Research) School of Chemical Engineering The University of New South Wales September, 2010 ABSTRACT Endocrine disrupting chemicals (EDCs) are chemicals that alter functions of the endocrine system and cause health effects in an intact organism, or progeny, or population, with reproductive, developmental, or carcinogenic consequences. In order to facilitate risk assessment of potential endocrine disrupting steroids that are present in ultra low concentrations in the Australian environment, there is a need to boost the analytical capacity for EDC detection. One strategy is to develop antibody-based techniques that can offer simple, cost-effective and reliable analysis with high throughput capacity and portability for real-time monitoring. This thesis describes the design and synthesis of hapten molecules, raising of specific antibodies, formatting and characterising of a series of sensitive competitive Enzyme-Linked Immunosorbent Assays (ELISAs) for 17β-estradiol (E2), 17α-ethynylestradiol (EE2), ethylestradiol-3-methyl ether (mestranol) and testosterone (T), including validation of their performance as fast and effective water monitoring tools. Application of the developed assays to investigate the levels of the target EDCs in bodies of water and efficiency of water treatment plants in urban and rural areas in New South Wales, Australia, is also discussed. 17α-Ethynylestradiol and related synthetic estrogens, are active ingredients of contraceptive pills and hormone therapy, and have been identified as potent EDCs (Warner and Jenkins, 2007).
    [Show full text]
  • Steroidal Estrogens
    FINAL Report on Carcinogens Background Document for Steroidal Estrogens December 13 - 14, 2000 Meeting of the NTP Board of Scientific Counselors Report on Carcinogens Subcommittee Prepared for the: U.S. Department of Health and Human Services Public Health Service National Toxicology Program Research Triangle Park, NC 27709 Prepared by: Technology Planning and Management Corporation Canterbury Hall, Suite 310 4815 Emperor Blvd Durham, NC 27703 Contract Number N01-ES-85421 Dec. 2000 RoC Background Document for Steroidal Estrogens Do not quote or cite Criteria for Listing Agents, Substances or Mixtures in the Report on Carcinogens U.S. Department of Health and Human Services National Toxicology Program Known to be Human Carcinogens: There is sufficient evidence of carcinogenicity from studies in humans, which indicates a causal relationship between exposure to the agent, substance or mixture and human cancer. Reasonably Anticipated to be Human Carcinogens: There is limited evidence of carcinogenicity from studies in humans which indicates that causal interpretation is credible but that alternative explanations such as chance, bias or confounding factors could not adequately be excluded; or There is sufficient evidence of carcinogenicity from studies in experimental animals which indicates there is an increased incidence of malignant and/or a combination of malignant and benign tumors: (1) in multiple species, or at multiple tissue sites, or (2) by multiple routes of exposure, or (3) to an unusual degree with regard to incidence, site or type of tumor or age at onset; or There is less than sufficient evidence of carcinogenicity in humans or laboratory animals, however; the agent, substance or mixture belongs to a well defined, structurally-related class of substances whose members are listed in a previous Report on Carcinogens as either a known to be human carcinogen, or reasonably anticipated to be human carcinogen or there is convincing relevant information that the agent acts through mechanisms indicating it would likely cause cancer in humans.
    [Show full text]
  • Anti-Doping Manual Revised Dec. 2018
    PGA TOUR Anti-Doping Program Manual REVISED DECEMBER 2018 Table of Contents How To Use This Manual .......................................................................................................................................................2 SECTION 1: Player Guide To Anti-Doping ...........................................................................................................................3 Who is covered by the Anti-Doping Program .........................................................................................................3 What substances and methods are banned ..........................................................................................................3 Am I liable for a prohibited substance in my body even if I did not intend to take the substance ........................3 What should players know about nutritional and health products ...................................................................3 Are there supplements that have been tested/certified as free from banned substances ........................3 What about medical treatment.................................................................................................................................4 What medications are permitted .............................................................................................................................4 Who conducts the testing and who will be tested ................................................................................................4 What are the steps in
    [Show full text]
  • Tools to Detect Estrogenic Activity in Environmental Waters
    Tools to detect estrogenic activity in environmental waters Author Leusch, Frederic Published 2008 Version Version of Record (VoR) Copyright Statement © 2008 Global Water Research Coalition. The attached file is reproduced here in accordance with the copyright policy of the publisher. Please refer to the publisher’s website for further information. Downloaded from http://hdl.handle.net/10072/134718 Link to published version http://www.globalwaterresearchcoalition.net Griffith Research Online https://research-repository.griffith.edu.au GWRC HHE-4Ta.qxd 11/7/07 1:08 PM Page 1 (2,1) Tools to Detect Estrogenic Activity in Environmental Waters IWA affiliate TOOLS TO DETECT ESTROGENIC ACTIVITY IN ENVIRONMENTAL WATERS by: Frederic DL Leusch, Ph.D. CRC Water Quality and Treatment 2008 Global Water Research Coalition: Global cooperation for the generation of water knowledge GWRC is a non-profit organization that serves as the collaborative mechanism for water research. The product the GWRC offers its members is water research information and knowledge. The Coalition will focus in water supply and wastewater issues and renewable water resources: the urban water cycle. The founding members of the GWRC are: the Awwa Research Foundation (US), CRC Water Quality and Treatment (Australia), EAWAG (Switzerland), Kiwa (Netherlands), Suez Environment – CIRSEE (France), Stowa – Foundation for Applied Water Research (Netherlands), PUB—Singapore, DVGW – TZW Water Technology Centre (Germany), UK Water Industry Research (UK), Veolia – Anjou Recherche (France), Water Environment Research Foundation (US), Water Research Commission (South Africa), Water Reuse Foundation and the Water Services Association of Australia. These organizations are all in charge of a national research program addressing the different parts of the water cycle.
    [Show full text]
  • Estrogenic Compounds: Chemical Characteristics, Detection Methods, Biological and Environmental Effects
    See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/324686974 Estrogenic Compounds: Chemical Characteristics, Detection Methods, Biological and Environmental Effects Article in Water Air and Soil Pollution · May 2018 DOI: 10.1007/s11270-018-3796-z CITATION READS 1 232 4 authors: Maria Tereza Pamplona-Silva Dânia Elisa Christofoletti Mazzeo São Paulo State University São Paulo State University 7 PUBLICATIONS 7 CITATIONS 19 PUBLICATIONS 564 CITATIONS SEE PROFILE SEE PROFILE Jaqueline Bianchi Maria Aparecida Marin-Morales São Paulo State University 7 PUBLICATIONS 102 CITATIONS 116 PUBLICATIONS 2,808 CITATIONS SEE PROFILE SEE PROFILE Some of the authors of this publication are also working on these related projects: AVALIAÇÃO DOS EFEITOS TÓXICOS E GENÉTICOS DE MICROCISTINAS SOB SISTEMAS TESTES ANIMAIS E VEGETAIS View project AVALIAÇÃO DOS EFEITOS TOXICOGENÉTICOS DE COMPOSTOS QUÍMICOS POLUIDORES DE RECURSOS HÍDRICOS, POR MEIO DE DIFERENTES BIOENSAIOS. View project All content following this page was uploaded by Maria Tereza Pamplona-Silva on 23 April 2018. The user has requested enhancement of the downloaded file. Water Air Soil Pollut (2018) 229:144 https://doi.org/10.1007/s11270-018-3796-z Estrogenic Compounds: Chemical Characteristics, Detection Methods, Biological and Environmental Effects Maria Tereza Pamplona-Silva & Dânia Elisa Christofoletti Mazzeo & Jaqueline Bianchi & Maria Aparecida Marin-Morales Received: 10 April 2017 /Accepted: 12 April 2018 # Springer International Publishing AG, part of Springer Nature 2018 Abstract Several chemical compounds are being stud- Keywords Endocrine disruptors . Environmental ied for their capacities to cause imbalances in several estrogenicity. Estrogen receptor. Estrogenic hormones . biological systems. Some of those are able to affect the Bioassay.
    [Show full text]
  • Cenestin™ (Synthetic Conjugated Estrogens, A) Tablets Physicians Package Insert
    NDA 20-992 Cenestin™ (synthetic conjugated estrogens, A) Tablets Physicians Package Insert Cenestin™ (synthetic conjugated estrogens, A) Tablets ] only PRESCRIBING INFORMATION ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CARCINOMA. Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is no evidence that natural estrogens are more or less hazardous than synthetic estrogens at equivalent estrogen doses. DESCRIPTION Synthetic conjugated estrogens, A tablets contain a blend of nine (9) synthetic estrogenic substances. The estrogenic substances are sodium estrone sulfate, sodium equilin sulfate, sodium 17α-dihydroequilin sulfate, sodium 17α-estradiol sulfate, sodium 17β-dihydroequilin sulfate, sodium 17α-dihydroequilenin sulfate, sodium 17β-dihydroequilenin sulfate, sodium equilenin sulfate and sodium 17β-estradiol sulfate. The structural formulae for these estrogens are: Page: 1 Date printed: Mar 23, 1999 NDA 20-992 Cenestin™ (synthetic conjugated estrogens, A) Tablets Physicians Package Insert O O NaO SO 3 C H NaO S NaO SO 18 21 5 3 C H NaO S 372.42 18 19 5 370.41 Sodium Estrone Sulfate Sodium Equilin Sulfate OH OH NaO SO NaO SO 3 C H NaO S 3 18 21 5 C18H21NaO5S 372.42 372.42 Sodium Dihydroequilin Sulfate 6RGLXPÃ 'LK\GURHTXLOLQÃ6XOIDWH OH OH NaO SO NaO SO 3 3 C H NaO S C18H23NaO5S 18 23 5 374.44 374.44 6RGLXPÃ (VWUDGLROÃ6XOIDWH 6RGLXPÃ (VWUDGLROÃ6XOIDWH O OH NaO3SO NaO3SO C18H17NaO5S C18H19NaO5S 368.39 370.41 Sodium Equilenin Sulfate 6RGLXPÃ 'LK\GURHTXLOHQLQÃ6XOIDWH OH NaO3SO C18H19NaO5S 370.41 6RGLXPÃ 'LK\GURHTXLOHQLQÃ6XOIDWH Tablets for oral administration, are available in 0.625 mg and 0.9 mg strengths of synthetic conjugated estrogens.
    [Show full text]
  • Anti-Doping Convention
    European Treaty Series - No. 135 Anti-Doping Convention Strasbourg, 16.XI.1989 Appendix – AMENDMENTS TO THE APPENDIX (approved by the Monitoring Group under Article 11.1.b of the Convention at its 51st meeting) (Strasbourg, 24 October 2019) THE 2020 PROHIBITED LIST - WORLD ANTI-DOPING CODE DATE OF ENTRY INTO FORCE: 1 JANUARY 2020 SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S.4.4, S.4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3. PROHIBITED SUBSTANCES 1-Testosterone (17β-hydroxy-5α-androst-1- en-3-one); S0. NON-APPROVED SUBSTANCES 4-Androstenediol (androst-4-ene-3β,17β-diol); 4-Hydroxytestosterone (4,17β- Any pharmacological substance which is not dihydroxyandrost-4-en-3one); addressed by any of the subsequent sections of 5-Androstenedione (androst-5-ene-3,17- the List and with no current approval by any dione); governmental regulatory health authority for 7α-hydroxy-DHEA; human therapeutic use (e.g. drugs under pre- 7β-hydroxy-DHEA; clinical or clinical development or discontinued, 7-Keto-DHEA; designer drugs, substances approved only for 19-Norandrostenediol (estr-4-ene-3,17-diol); veterinary use) is prohibited at all times. 19-Norandrostenedione (estr-4-ene-3,17- dione); S1. ANABOLIC AGENTS Androstanolone (5α-dihydrotestosterone, 17β- hydroxy-5αandrostan-3-one); Anabolic agents are prohibited. Androstenediol (androst-5-ene-3β,17β-diol);
    [Show full text]